Saltar al contenido
Merck

The discovery of potent antagonists of NPBWR1 (GPR7).

Bioorganic & medicinal chemistry letters (2011-12-27)
F Anthony Romero, Nicholas B Hastings, Remond Moningka, Zhiqiang Guo, Ming Wang, Jerry Di Salvo, Ying Lei, Dorina Trusca, Qiaolin Deng, Vincent Tong, Jenna L Terebetski, Richard G Ball, Feroze Ujjainwalla
RESUMEN

The synthesis and evaluation of small molecule antagonists of the G protein-coupled receptor NPBWR1 (GPR7) are reported for the first time. [4-(5-Chloropyridin-2-yl)piperazin-1-yl][(1S,2S,4R)-4-{[(1R)-1-(4-methoxyphenyl)ethyl]amino}-2-(thiophen-3-yl)cyclohexyl]methanone (1) emerged as a hit from a high-throughput screen. Examination of substituents that focused on replacing the 5-chloropyridine and 4-methoxybenzylamino groups of 1 led to the identification of compounds that exhibited subnanomolar potencies as low as 660pM (9k) in the functional assay and 200pM in the binding assay (9i).

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Benzylamine, ReagentPlus®, 99%
Sigma-Aldrich
Benzylamine, purified by redistillation, ≥99.5%
Sigma-Aldrich
Benzylamine hydrochloride
Supelco
Benzylamine, for GC derivatization, LiChropur, ≥99.0%